CalciMedica (NASDAQ:CALC) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock.

CalciMedica Stock Up 2.1 %

Shares of NASDAQ:CALC opened at $1.95 on Tuesday. The stock has a market capitalization of $26.29 million, a PE ratio of -1.81 and a beta of 1.20. The firm’s 50 day moving average price is $2.34 and its 200-day moving average price is $3.11. CalciMedica has a twelve month low of $1.81 and a twelve month high of $6.27.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Thursday, March 27th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.14. Analysts expect that CalciMedica will post -2.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CalciMedica

Several institutional investors and hedge funds have recently bought and sold shares of CALC. Wealthedge Investment Advisors LLC bought a new position in shares of CalciMedica in the fourth quarter worth about $98,000. Stonepine Capital Management LLC purchased a new stake in CalciMedica in the 4th quarter worth approximately $1,660,000. Millennium Management LLC increased its holdings in CalciMedica by 30.5% in the 4th quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock worth $255,000 after acquiring an additional 16,824 shares in the last quarter. Deerfield Management Company L.P. Series C raised its stake in CalciMedica by 30.0% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,300,000 shares of the company’s stock worth $4,602,000 after acquiring an additional 300,000 shares during the period. Finally, Cetera Investment Advisers lifted its holdings in CalciMedica by 37.1% during the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock valued at $60,000 after purchasing an additional 4,566 shares in the last quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.